Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
agent, andeach, ASUNo, ATM, beta, deducting, eligibleresearch, evolution, experimental, FASB, footing, incremental, instruction, instrumen, intervention, Januar, Leerink, lengthen, November, ofeach, optionsare, overhead, pharmacodynamic, prospective, retrospective, ts, underwriter, underwriting, underwritten, warrantat
Removed:
abbreviated, accept, accretion, acute, adapt, adding, adequacy, adjusted, administered, Affordable, al, allegation, alleging, AML, amortization, ANDA, applying, area, assuming, assure, attack, Bruton, BTKi, California, called, CCPA, CDK, characterized, CLL, code, coding, cognizant, commonplace, competence, component, conform, connected, Continental, daily, delaying, Department, description, diffuse, disrupt, disrupted, DLBCL, dollar, double, duly, economy, Education, evolve, execute, executed, expanding, family, field, forecasted, GDPR, gene, geographic, impairment, imposing, inadvertently, injunctive, inspection, instrument, intent, intentional, interpreting, interruption, invent, inventor, investee, jeopardized, judged, June, legislative, leukemia, limitation, lymphocytic, lymphoma, managing, mantle, MCL, messenger, misleading, modal, mRNA, MYC, myelodysplastic, myeloid, patenting, performed, periodically, powering, prescribing, productivity, prosecuted, prosecutorial, quoted, reclassified, Reconciliation, registry, regulator, resale, restatement, RNA, Salzburg, Sciabacucchi, settlement, spread, statutory, studied, supplier, Switching, syndrome, tolerable, Transfer, transportation, Trust, tyrosine, undergone, updated, validate, vendor, withheld
Financial report summary
?Competition
Bristol-Myers Squibb • Pfizer • Gilead Sciences • Macrogenics • Cyclacel Pharmaceuticals • Mersana Therapeutics • CytomX Therapeutics • Abbvie • Prelude Therapeutics • Kronos BioManagement Discussion
- Research and development expenses decreased by approximately $6.4 million for the three months ended March 31, 2024 compared to the three months ended March 31, 2023. The decrease for the three months ended March 31, 2024 compared with the same period in 2023 is primarily the result of decreases in manufacturing services associated with our ADC program of approximately $2.6 million, research services of approximately $2.6 million and personnel related expenses of approximately $1.1 million.
- General and administrative expenses decreased by approximately $1.6 million for the three months ended March 31, 2024 compared to the three months ended March 31, 2023. This decrease was primarily due to decreases in personnel related expenses of approximately $0.6 million, professional services of $0.5 million and facilities and other corporate overhead expenses of $0.3 million.
- The change in fair value of warrant liabilities for the three months ended March 31, 2024 is primarily due to the increase in the closing price of our common stock from $1.18 as of December 31, 2023 to $5.06 as of March 31, 2024. For the three months ended March 31, 2023, the change in the stock price was insignificant.